Eton Pharmaceuticals (ETON) Interest & Investment Income (2018 - 2019)
Eton Pharmaceuticals (ETON) posted Interest & Investment Income of $77000.0 for Q3 2019, down 23.0% sequentially from $100000.0 in Q2 2019, and up 208.0% YoY from $25000.0 in Q3 2018.
Eton Pharmaceuticals (ETON) Interest & Investment Income (2018 - 2019) Analysis & Trends
Eton Pharmaceuticals has reported Interest & Investment Income for 2 years, with the latest figure at $77000.0 in Q3 2019.
- Quarterly Interest & Investment Income rose 208.0% year-over-year to $77000.0 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $403000.0 (changed N/A YoY) and the FY2018 annual result came in at $164000.0, up 368.57% from the prior year.
- Interest & Investment Income fell to $77000.0 in Q3 2019 per ETON's latest filing, from $100000.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $144000.0 in Q1 2019 and troughed at $25000.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 154.39 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 31.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 12.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Eton Pharmaceuticals | 1.65 Bn | 1.62 Bn | 25.41 Mn | -1.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 77,000.00 |
| Jun 30, 2019 | 100,000.00 |
| Mar 31, 2019 | 144,000.00 |
| Dec 31, 2018 | 82,000.00 |
| Sep 30, 2018 | 25,000.00 |
| Jun 30, 2018 | 28,000.00 |
| Mar 31, 2018 | 29,000.00 |